Medicines in development

Building on the deep heritage of our shareholders, our scientists continue to work with GSK’s R&D team to identify new ways to reduce the impact of HIV on the 35 million people living with the virus.

Although there have been significant advances in HIV therapy in recent years, many treatment-related challenges persist. New medicines need to support a broad range of patients with diverse needs and offer continued improvements in efficacy as well as other important patient-focused areas such as tolerability, safety, resistance, dosing schedules, drug interactions and convenience.

In addition, recent results with PrEP (pre-exposure prophylaxis) for the prevention of HIV infection warrant further exploration of new delivery technologies to give people at greatest risk of acquiring HIV infection a number of prevention methods from which to choose.

 

Phase II/III clinical development pipeline

ProductClassPhase

dolutegravir/rilpivirine* STR

Integrase inhibitor/NNRTI

III

LA cabotegravir + LA rilpivirine*

(for intramuscular injection)

Integrase inhibitor + NNRTI

IIb

(for treatment of HIV infection)

LA cabotegravir

(for intramuscular injection)

Integrase inhibitor

IIa

(for prevention of HIV infection)

*in collaboration with Janssen

LA = long-acting; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; STR = single tablet regimen

 

If you are an investigator working on one of the clinical research programmes and think you may be impacted by the news that ViiV Healthcare has acquired BMS’ HIV R&D pipeline – please see this letter to investigators.